US 12,077,609 B2
Variable lymphocyte receptors that target the brain extracellular matrix and methods of use
Eric V. Shusta, Madison, WI (US); Benjamin Umlauf, Madison, WI (US); Brantley Herrin, Atlanta, GA (US); Paul Clark, Madison, WI (US); and John Kuo, Austin, TX (US)
Assigned to WISCONSIN ALUMNI RESEARCH FOUNDATION, Madison, WI (US); and EMORY UNIVERSITY, Atlanta, GA (US)
Appl. No. 17/414,581
Filed by Wisconsin Alumni Research Foundation, Madison, WI (US); and Emory University, Atlanta, GA (US)
PCT Filed Dec. 19, 2019, PCT No. PCT/US2019/067579
§ 371(c)(1), (2) Date Jun. 16, 2021,
PCT Pub. No. WO2020/132301, PCT Pub. Date Jun. 25, 2020.
Claims priority of provisional application 62/783,475, filed on Dec. 21, 2018.
Prior Publication US 2022/0041659 A1, Feb. 10, 2022
Int. Cl. C07K 7/08 (2006.01); A61K 38/00 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 7/06 (2006.01); C12N 15/86 (2006.01)
CPC C07K 7/08 (2013.01) [A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 7/06 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01)] 30 Claims
 
1. An isolated polypeptide comprising a variable lymphocyte receptor (VLR) comprising the six following regions:
 
 (i)
 
 SEQ ID NO: 11
 
 (TVKCHS),
 
 
 
 (ii)
 
 SEQ ID NO: 12
 
 (ILRLYS),
 
 
 
 (iii)
 
 SEQ ID NO: 13
 
 (KLYISW),
 
 
 
 (iv)
 
 SEQ ID NO: 14
 
 (HLSLGY),
 
 
 
 (v)
 
 SEQ ID NO: 15
 
 (HIWLLN),
 
 and
 
 
 
 (vi)
 
 (SEQ ID NO: 8)
 
 (SIVNLQGHGGVD),
wherein the isolated polypeptide is able to specifically bind to brain extracellular matrix (ECM) in vivo.